
## K Jagannadha Sastry

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5739758/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Expansion of Candidate HPV-Specific T Cells in the Tumor Microenvironment during Chemoradiotherapy Is Prognostic in HPV16+ Cancers. Cancer Immunology Research, 2022, 10, 259-271.	1.6	10
2	Mucosal Vaccination With Recombinant Tm-WAP49 Protein Induces Protective Humoral and Cellular Immunity Against Experimental Trichuriasis in AKR Mice. Frontiers in Immunology, 2022, 13, 800295.	2.2	4
3	Efficacy of oleandrin and PBI-05204 against bovine viruses of importance to commercial cattle health. Antiviral Chemistry and Chemotherapy, 2022, 30, 204020662211039.	0.3	1
4	Mucoadhesive wafers composed of binary polymer blends for sublingual delivery and preservation of protein vaccines. Journal of Controlled Release, 2021, 330, 427-437.	4.8	10
5	Gut microbiome diversity is an independent predictor of survival in cervical cancer patients receiving chemoradiation. Communications Biology, 2021, 4, 237.	2.0	62
6	Antiviral effects of oleandrin. Journal of the American College of Emergency Physicians Open, 2021, 2, e12469.	0.4	1
7	Antiviral activity of oleandrin and a defined extract of Nerium oleander against SARS-CoV-2. Biomedicine and Pharmacotherapy, 2021, 138, 111457.	2.5	23
8	A recombinant bovine adenoviral mucosal vaccine expressing mycobacterial antigen-85B generates robust protection against tuberculosis in mice. Cell Reports Medicine, 2021, 2, 100372.	3.3	16
9	Preventive Efficacy of a Tenofovir Alafenamide Fumarate Nanofluidic Implant in SHIV hallenged Nonhuman Primates. Advanced Therapeutics, 2021, 4, 2000163.	1.6	28
10	Antiviral Effects of Oleandrin. Journal of Experimental Pharmacology, 2020, Volume 12, 503-515.	1.5	13
11	Viral load Reduction in SHIV-Positive Nonhuman Primates via Long-Acting Subcutaneous Tenofovir Alafenamide Fumarate Release from a Nanofluidic Implant. Pharmaceutics, 2020, 12, 981.	2.0	13
12	Effect of Antibiotics on Gut and Vaginal Microbiomes Associated with Cervical Cancer Development in Mice. Cancer Prevention Research, 2020, 13, 997-1006.	0.7	9
13	Intranasal Therapeutic Peptide Vaccine Promotes Efficient Induction and Trafficking of Cytotoxic T Cell Response for the Clearance of HPV Vaginal Tumors. Vaccines, 2020, 8, 259.	2.1	7
14	Trans-urocanic acid enhances tenofovir alafenamide stability for long-acting HIV applications. International Journal of Pharmaceutics, 2020, 587, 119623.	2.6	10
15	Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV+ oral cancer. , 2019, 7, 252.		57
16	Lymphocytes upregulate CD36 in adipose tissue and liver. Adipocyte, 2019, 8, 154-163.	1.3	15
17	Divergent HIV-1-Directed Immune Responses Generated by Systemic and Mucosal Immunization with Replicating Single-Cycle Adenoviruses in Rhesus Macaques. Journal of Virology, 2019, 93, .	1.5	11
18	Regulation of cyclin T1 during HIV replication and latency establishment in human memory CD4 T cells. Virology Journal, 2019, 16, 22.	1.4	8

K JAGANNADHA SASTRY

#	Article	IF	CITATIONS
19	The Botanical Glycoside Oleandrin Inhibits Human T-cell Leukemia Virus Type-1 Infectivity and Env-Dependent Virological Synapse Formation. , 2019, 11, .		9
20	Adipocytes impair efficacy of antiretroviral therapy. Antiviral Research, 2018, 154, 140-148.	1.9	44
21	Trichuris muris whey acidic protein induces type 2 protective immunity against whipworm. PLoS Pathogens, 2018, 14, e1007273.	2.1	18
22	Mucosal HPV E6/E7 Peptide Vaccination in Combination with Immune Checkpoint Modulation Induces Regression of HPV+ Oral Cancers. Cancer Research, 2018, 78, 5327-5339.	0.4	20
23	Prophylactic Sublingual Immunization with Mycobacterium tuberculosis Subunit Vaccine Incorporating the Natural Killer T Cell Agonist Alpha-Galactosylceramide Enhances Protective Immunity to Limit Pulmonary and Extra-Pulmonary Bacterial Burden in Mice. Vaccines, 2017, 5, 47.	2.1	19
24	Minimally invasive monitoring of CD4 T cells at multiple mucosal tissues after intranasal vaccination in rhesus macaques. PLoS ONE, 2017, 12, e0188807.	1.1	3
25	Age- and Sex-associated Differences in Phenotypic and Functional Characteristics of Peripheral Blood Lymphocytes in Chimpanzees (). Journal of the American Association for Laboratory Animal Science, 2017, 56, 509-519.	0.6	7
26	Intranasal Vaccination Affords Localization and Persistence of Antigen-Specific CD8+ T Lymphocytes in the Female Reproductive Tract. Vaccines, 2016, 4, 7.	2.1	4
27	Infectious SIV resides in adipose tissue and induces metabolic defects in chronically infected rhesus macaques. Retrovirology, 2016, 13, 30.	0.9	46
28	The Hygiene Hypothesis and Its Inconvenient Truths about Helminth Infections. PLoS Neglected Tropical Diseases, 2016, 10, e0004944.	1.3	46
29	Sublingual injection of microparticles containing glycolipid ligands for NKT cells and subunit vaccines induces antibody responses in oral cavity. Carbohydrate Research, 2015, 405, 87-92.	1.1	4
30	Unique potential of 4-1BB agonist antibody to promote durable regression of HPV <sup>+</sup> tumors when combined with an E6/E7 peptide vaccine. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E5290-9.	3.3	79
31	Amplified and Persistent Immune Responses Generated by Single-Cycle Replicating Adenovirus Vaccines. Journal of Virology, 2015, 89, 669-675.	1.5	37
32	Enhancement of Mucosal Immunogenicity of Viral Vectored Vaccines by the NKT Cell Agonist Alpha-Galactosylceramide as Adjuvant. Vaccines, 2014, 2, 686-706.	2.1	20
33	Natural killer T cell and TLR9 agonists as mucosal adjuvants for sublingual vaccination with clade C HIV-1 envelope protein. Vaccine, 2014, 32, 6934-6940.	1.7	23
34	Procedures for Mucosal Immunization and Analyses of Cellular Immune Response to Candidate HIV Vaccines in Murine and Nonhuman Primate Models. Methods in Molecular Biology, 2014, 1184, 417-455.	0.4	4
35	Sublingual Vaccination Induces Mucosal and Systemic Adaptive Immunity for Protection against Lung Tumor Challenge. PLoS ONE, 2014, 9, e90001.	1.1	13
36	Nerium oleander derived cardiac glycoside oleandrin is a novel inhibitor of HIV infectivity. Fìtoterapìâ, 2013, 84, 32-39.	1.1	42

#	Article	IF	CITATIONS
37	HIV-1 Vpr Protein Inhibits Telomerase Activity via the EDD-DDB1-VPRBP E3 Ligase Complex. Journal of Biological Chemistry, 2013, 288, 15474-15480.	1.6	44
38	Phenotypic and Functional Characterization of Lymphocytes from Different Age Groups of Bolivian Squirrel Monkeys (Saimiri boliviensis boliviensis). PLoS ONE, 2013, 8, e79836.	1.1	17
39	Comparison of Systemic and Mucosal Immunization with Helper-Dependent Adenoviruses for Vaccination against Mucosal Challenge with SHIV. PLoS ONE, 2013, 8, e67574.	1.1	22
40	Functional Impairment of Central Memory CD4 T Cells Is a Potential Early Prognostic Marker for Changing Viral Load in SHIV-Infected Rhesus Macaques. PLoS ONE, 2011, 6, e19607.	1.1	12
41	Increased inherent intestinal granzyme B expression may be associated with SIV pathogenesis in Asian non-human primates. Journal of Medical Primatology, 2011, 40, 414-426.	0.3	6
42	Intranasal but not intravenous delivery of the adjuvant αâ€galactosylceramide permits repeated stimulation of natural killer T cells in the lung. European Journal of Immunology, 2011, 41, 3312-3322.	1.6	31
43	Multicolor Flow Cytometry Analyses of Cellular Immune Response in Rhesus Macaques. Journal of Visualized Experiments, 2010, , .	0.2	6
44	Norwalk virus does not replicate in human macrophages or dendritic cells derived from the peripheral blood of susceptible humans. Virology, 2010, 406, 1-11.	1.1	88
45	TSLP production by epithelial cells exposed to immunodeficiency virus triggers DC-mediated mucosal infection of CD4+ T cells. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 16776-16781.	3.3	49
46	Protection against Mucosal SHIV Challenge by Peptide and Helper-Dependent Adenovirus Vaccines. Viruses, 2009, 1, 920-938.	1.5	26
47	Alpha-galactosylceramide is an effective mucosal adjuvant for repeated intranasal or oral delivery of HIV peptide antigens. Vaccine, 2009, 27, 3335-3341.	1.7	67
48	Comparison of Replication-Competent, First Generation, and Helper-Dependent Adenoviral Vaccines. PLoS ONE, 2009, 4, e5059.	1.1	61
49	Selective induction of cell-mediated immunity and protection of rhesus macaques from chronic SHIVKU2 infection by prophylactic vaccination with a conserved HIV-1 envelope peptide-cocktail. Virology, 2008, 370, 130-141.	1.1	14
50	Mapping of the CXCR4 Binding Site within Variable Region 3 of the Feline Immunodeficiency Virus Surface Glycoprotein. Journal of Virology, 2008, 82, 9134-9142.	1.5	23
51	Human Endogenous Retrovirus K Triggers an Antigen-Specific Immune Response in Breast Cancer Patients. Cancer Research, 2008, 68, 5869-5877.	0.4	169
52	Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection. Vaccine, 2007, 25, 3302-3310.	1.7	40
53	Oral immunization of rhesus macaques with adenoviral HIV vaccines using enteric-coated capsules. Vaccine, 2007, 25, 8687-8701.	1.7	52
54	Critical role of Arg59 in the high-affinity gp120-binding region of CD4 for human immunodeficiency virus type 1 infection. Virology, 2007, 363, 69-78.	1.1	8

#	Article	IF	CITATIONS
55	Sequential CD134-CXCR4 Interactions in Feline Immunodeficiency Virus (FIV): Soluble CD134 Activates FIV Env for CXCR4-Dependent Entry and Reveals a Cryptic Neutralization Epitope. Journal of Virology, 2006, 80, 3088-3091.	1.5	36
56	Inverse correlation of cellular immune responses specific to synthetic peptides from the E6 and E7 oncoproteins of HPV-16 with recurrence of cervical intraepithelial neoplasia in a cross-sectional study. Gynecologic Oncology, 2005, 99, S251-S261.	0.6	37
57	Improving the Sensitivity of the ELISPOT Analyses of Antigen-Specific Cellular Immune Responses in Rhesus Macaques. , 2005, 302, 153-166.		2
58	Protection by dendritic cells-based HIV synthetic peptide cocktail vaccine: preclinical studies in the SHIV-rhesus model. Vaccine, 2005, 23, 2154-2159.	1.7	26
59	Extramedullary Hematopoiesis in the Mandibular Lymph Node of Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys (Macaca mulatta): A Report of Three Cases. Veterinary Pathology, 2004, 41, 186-190.	0.8	2
60	SHIV transmission and susceptibility to re-exposure through social contact following vaccination with an HIV synthetic peptide-cocktail: a case study. Journal of Medical Primatology, 2004, 33, 10-15.	0.3	3
61	A two-codon mutant of cholera toxin lacking ADP-ribosylating activity functions as an effective adjuvant for eliciting mucosal and systemic cellular immune responses to peptide antigens. Vaccine, 2004, 23, 555-565.	1.7	9
62	Animal Models in AIDS Research. , 2004, , 61-77.		0
63	Flow cytometric analysis of macaque whole blood for antigen-specific intracellular cytokine production by T lymphocytes. Journal of Medical Primatology, 2003, 32, 23-30.	0.3	7
64	Dendritic cells enhance detection of antigenâ€ <b>s</b> pecific cellular immune responses by lymphocytes from rhesus macaques immunized with an HIV envelope peptide cocktail vaccine. Journal of Medical Primatology, 2003, 32, 67-73.	0.3	27
65	A post-CD4-binding step involving interaction of the V3 region of viral gp120 with host cell surface glycosphingolipids is common to entry and infection by diverse HIV-1 strains. Antiviral Research, 2002, 56, 233-251.	1.9	37
66	Synthetic peptide-based HIV vaccine induces protective immunity in SHIV-rhesus model. , 2002, , 706-707.		0
67	Protection against chronic infection and AIDS by an HIV envelope peptide-cocktail vaccine in a pathogenic SHIV-rhesus model. Vaccine, 2001, 20, 813-825.	1.7	36
68	Impairment of antigen-specific cellular immune responses under simulated microgravity conditions. In Vitro Cellular and Developmental Biology - Animal, 2001, 37, 203-208.	0.7	16
69	Differences in functional immune responses of high vs. low hardy healthy individuals. Journal of Behavioral Medicine, 2001, 24, 219-229.	1.1	19
70	IMPAIRMENT OF ANTIGEN-SPECIFIC CELLULAR IMMUNE RESPONSES UNDER SIMULATED MICROGRAVITY CONDITIONS. In Vitro Cellular and Developmental Biology - Animal, 2001, 37, 203.	0.7	6
71	Evaluation of cellular immune responses in rhesus monkeys subjected to adenovirus-mediated gene transfer into the cervix. Cancer Gene Therapy, 1999, 6, 220-227.	2.2	4
72	Evidence for specific immune response against P210 BCR-ABL in long-term remission CML patients treated with interferon. Leukemia, 1998, 12, 155-163.	3.3	31

#	Article	IF	CITATIONS
73	Presence of HLA-C-Restricted Cytotoxic T-Lymphocyte Responses in Long-Term Nonprogressors Infected with Human Immunodeficiency Virus. Viral Immunology, 1998, 11, 119-129.	0.6	26
74	A Synthetic Peptide from the First Conserved Region in the Envelope Protein gp160 Is a Strong T-Cell Epitope in HIV-Infected Chimpanzees and Humans. Viral Immunology, 1998, 11, 147-158.	0.6	22
75	Cross-reactive T-cell proliferative responses to V3 peptides corresponding to different geographical HIV-1 isolates in HIV-seropositive individuals. Journal of Clinical Immunology, 1996, 16, 115-124.	2.0	7
76	Transgene expression in the rhesus cervix mediated by an adenovirus expressing β-galactosidase. American Journal of Obstetrics and Gynecology, 1996, 174, 1094-1101.	0.7	13
77	Studies on V3-specific cross-reactive T-cell responses in chimpanzees chronically infected with HIV-1111B. Aids, 1995, 9, 567-572.	1.0	10
78	Cross-Reactive Cytotoxic T Lymphocytes Induced by V3 Loop Synthetic Peptides from Different Strains of Human Immunodeficiency Virus Type 1. Virology, 1995, 211, 261-267.	1.1	22
79	Studies on in vivo induction of HIV-1 envelope-specific cytotoxic T lymphocytes by synthetic peptides from the V3 loop region of HIV-1 IIIB gp120. Cellular Immunology, 1995, 160, 217-223.	1.4	28
80	Studies on in Vivo Induction of Cytotoxic T Lymphocyte Responses by Synthetic Peptides from E6 and E7 Oncoproteins of Human Papillomavirus Type 16. Viral Immunology, 1995, 8, 165-174.	0.6	30
81	Use of Helper T Cell-Inducing Peptides from Conserved Regions in HIV-1 <i>env</i> in a Noncovalent Mixture with a CTL-Inducing V3-Loop Peptide for <i>in Vivo</i> Induction of Long-Lasting Systemic CTL Response. Viral Immunology, 1994, 7, 189-197.	0.6	6
82	Effects of influenza virus-specific cytotoxic T-lymphocyte responses induced by a synthetic nucleoprotein peptide on the survival of mice challenged with a lethal dose of virus. Vaccine, 1994, 12, 1281-1287.	1.7	15
83	Induction of Human Immunodeficiency Virus-Specific T Cell Responses in Rhesus Monkeys by Synthetic Peptides from gp160. AIDS Research and Human Retroviruses, 1993, 9, 235-240.	0.5	15
84	Inhibition of human immunodeficiency virus type 1 infection and syncytium formation in human cells by V3 loop synthetic peptides from gp120. Journal of Virology, 1993, 67, 6841-6846.	1.5	48
85	Rapid in vivo induction of HIV-specific cd8+ cytotoxic T lymphocytes by a 15-amino acid unmodified free peptide from the immunodominant V3-loop of GP120. Virology, 1992, 188, 502-509.	1.1	41
86	Identification of T-cell epitopes without B-cell activity in the first and second conserved regions of the HIV Env protein. Aids, 1991, 5, 699-708.	1.0	26
87	HIV-1 tat gene induces tumor necrosis factor-beta (lymphotoxin) in a human B-lymphoblastoid cell line. Journal of Biological Chemistry, 1990, 265, 20091-3.	1.6	85
88	A novel HIV vaccine strategy. Hematologic Pathology, 1990, 4, 157-9.	0.2	2
89	Adenosine kinase deficiency in tritiated deoxyadenosine-resistant mouse S49 lymphoma cell lines. Biochemical Genetics, 1987, 25, 765-777.	0.8	4
90	Selective overproduction of human dihydrofolate reductase in a methotrexate-resistant human-mouse somatic cell hybrid. Biochemical and Biophysical Research Communications, 1985, 132, 795-803.	1.0	6

#	Article	IF	CITATIONS
91	Synthesis of exocellular proteins during the exponential and stationary phase of growth ofBacillus megaterium. Folia Microbiologica, 1981, 26, 73-77.	1.1	4
92	The Gut and Cervical Microbiome Promote Immune Activation and Response to Chemoradiation in Cervical Cancer. SSRN Electronic Journal, 0, , .	0.4	3